Aprea Therapeutics’ (APRE) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Separately, Wedbush restated an outperform rating and issued a $9.00 price objective on shares of Aprea Therapeutics in a report […]
More Stories
Richard C. Young & CO. LTD. Sells 1,310 Shares of The Hershey Company (NYSE:HSY)
Richard C. Young & CO. LTD. reduced its stake in shares of The Hershey Company (NYSE:HSY – Free Report) by...
Mutual of America Capital Management LLC Has $10.85 Million Stock Holdings in KKR & Co. Inc. (NYSE:KKR)
Mutual of America Capital Management LLC lowered its stake in shares of KKR & Co. Inc. (NYSE:KKR – Free Report)...
ETF Store Inc. Trims Stock Position in Invesco BulletShares 2024 Corporate Bond ETF (NASDAQ:BSCO)
ETF Store Inc. lessened its stake in shares of Invesco BulletShares 2024 Corporate Bond ETF (NASDAQ:BSCO – Free Report) by...
Corbyn Investment Management Inc. MD Cuts Stake in Primis Financial Corp. (NASDAQ:FRST)
Corbyn Investment Management Inc. MD lowered its holdings in shares of Primis Financial Corp. (NASDAQ:FRST – Free Report) by 2.9%...
Vanguard Intermediate-Term Treasury Index ETF (NASDAQ:VGIT) Shares Bought by ETF Store Inc.
ETF Store Inc. grew its holdings in shares of Vanguard Intermediate-Term Treasury Index ETF (NASDAQ:VGIT – Free Report) by 62.8%...
Taurus Asset Management LLC Sells 29 Shares of Eli Lilly and Company (NYSE:LLY)
Taurus Asset Management LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.1%...